INNOVATIVE DRUGS
Innovative Specialty Drugs
China-originated oncology drugs approved by the NMPA and/or FDA, plus overseas specialty medicines available through the Boao Lecheng pilot zone.
Showing 9 of 19
Zanubrutinib
BRUKINSA · BeOne (BeiGene)
The first China-originated cancer drug approved by the US FDA; the head-to-head ALPINE trial showed superiority over ibrutinib with better cardiac safety. 2024 global sales reached RMB 18.86B — the first Chinese oncology blockbuster.
Target：Bruton tyrosine kinase (BTK)
First Approved：US FDA · 2019
Maturity：FDA / EMA / NMPA approved · 70+ countries
Price & Coverage：Listed in China NRDL — out-of-pocket cost far below overseas markets
Ciltacabtagene Autoleucel
Carvykti · Legend Biotech / Janssen
China-originated, globally leading BCMA CAR-T: the CARTITUDE program shows best-in-class deep responses, with annual sales approaching US$1B — an icon of Chinese pharma globalization.
Target：B-cell maturation antigen (BCMA)
First Approved：US FDA · 2022
Maturity：FDA / EMA / NMPA approved
Price & Coverage：US list price ~US$465k per course; accessibility in China improving after NMPA approval
Axicabtagene Ciloleucel
FKC876 · Fosun Kite
The first CAR-T cell therapy approved in China (June 2021) for relapsed/refractory large B-cell lymphoma; the first commercial patient achieved complete remission at Ruijin Hospital — opening the era of commercial cell therapy in China.
Target：CD19 (B-cell surface antigen)
First Approved：NMPA · 2021 (first CAR-T approved in China)
Maturity：NMPA approved · r/r large B-cell lymphoma
Price & Coverage：Approx. RMB 1.2M per course; not in NRDL, partly covered by city-level Huiminbao and commercial insurance
Relmacabtagene Autoleucel
JWCAR029 · JW Therapeutics
The second CAR-T approved in China; the RELIANCE study showed deep responses in r/r large B-cell lymphoma, with later expansion into mantle cell lymphoma and ALL.
Target：CD19 (B-cell surface antigen)
First Approved：NMPA · 2021
Maturity：NMPA approved · lymphoma and ALL
Price & Coverage：Approx. RMB 1.29M per course; not in NRDL, partly covered by Huiminbao programs
Equecabtagene Autoleucel
Fucaso · Innovent / IASO Bio
The world’s first fully human BCMA CAR-T; the FUMANBA-1 study showed class-leading overall response rates, offering durable deep remissions for r/r multiple myeloma.
Target：BCMA (fully human)
First Approved：NMPA · 2023
Maturity：NMPA approved · r/r multiple myeloma
Price & Coverage：RMB 1M+ per course; partly covered by Huiminbao and commercial insurance
Cadonilimab
Kaitanni · Akeso
The world’s first approved PD-1/CTLA-4 bispecific antibody (2022, cervical cancer), later expanded to first-line gastric cancer — delivering dual-checkpoint efficacy with more manageable toxicity in a single molecule.
Target：Dual immune checkpoints PD-1 + CTLA-4
First Approved：NMPA · 2022 (world’s first bispecific dual-checkpoint antibody)
Maturity：NMPA approved · cervical, gastric cancers
Price & Coverage：Included in NRDL via national negotiation — out-of-pocket cost sharply reduced
Toripalimab
LOQTORZI · Junshi Biosciences
The first China-made PD-1 inhibitor approved by the US FDA (2023, nasopharyngeal carcinoma), with 10+ domestic indications, most reimbursed by national insurance at a fraction of import prices.
Target：Programmed cell death protein 1 (PD-1)
First Approved：NMPA · 2018; FDA · 2023
Maturity：FDA / NMPA approved (first for NPC)
Price & Coverage：Multiple indications in NRDL — annual cost far below imported PD-1 inhibitors
Tislelizumab
TEVIMBRA · BeOne (BeiGene)
BeiGene’s in-house PD-1 covering 10+ indications — lung, ESCC, classical Hodgkin lymphoma — broadly reimbursed in China; subsequently approved in the EU and US, among the few Chinese PD-1s in Western markets.
Target：Programmed cell death protein 1 (PD-1)
First Approved：NMPA · 2019; EMA · 2023; FDA · 2024
Maturity：NMPA / EMA / FDA approved · ESCC and more
Price & Coverage：Multiple indications in NRDL
Sintilimab
Tyvyt · Innovent / Lilly
Co-developed by Innovent and Lilly; the ORIENT program spans NSCLC, gastric cancer and Hodgkin lymphoma. Among the first PD-1 inhibitors in China’s NRDL — a milestone in making immunotherapy affordable.
Target：Programmed cell death protein 1 (PD-1)
First Approved：NMPA · 2018
Maturity：NMPA approved · among first PD-1s in NRDL
Price & Coverage：Entered NRDL early (2019) — annual cost reduced to the tens-of-thousands RMB range
Lecheng Access
The Boao Lecheng International Medical Tourism Pilot Zone (Hainan) operates under special licensed-medical policies: drugs and devices already marketed overseas but not yet approved in mainland China can be imported and used under special-access regulation. We can assess whether your treatment plan qualifies for the Lecheng pathway.
View details · Boao LechengRequest Case Review
Share your contact details, confirmed diagnosis and main question. No medical files needed at this stage. A clinical coordinator will contact you within 24-48 hours.
Book a Consultation